The rise of immuno-oncology in China: a challenge to western dominance?
Lancet Oncol
.
2023 May;24(5):439-441.
doi: 10.1016/S1470-2045(23)00026-8.
Authors
Mark P Lythgoe
1
,
Grant Lewison
2
,
Ajay Aggarwal
3
,
Chris Booth
4
,
Mark Lawler
5
,
Dario Trapani
6
,
Manju Sengar
7
,
Richard Sullivan
2
Affiliations
1
Department of Surgery and Cancer, Imperial College London, London, UK. Electronic address: M.Lythgoe@imperial.ac.uk.
2
King's College London, Institute of Cancer Policy (Global Oncology Group), London, UK.
3
Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK.
4
Departments of Oncology & Public Health Sciences, Queen's University, Kingston, ON, Canada.
5
Patrick G Johnston Centre for Cancer Research, Faculty of Medicine, Health and Life Sciences, Queen's University Belfast, Belfast, UK.
6
Division of Early Drug Development for Innovative Therapies, European Institute of Oncology (IEO) IRCCS, Milan, Italy.
7
Department of Medical Oncology, Tata Memorial Centre, Mumbai, India.
PMID:
37142369
DOI:
10.1016/S1470-2045(23)00026-8
No abstract available
MeSH terms
China / epidemiology
Humans
Immunotherapy / adverse effects
Medical Oncology
Neoplasms* / epidemiology
Neoplasms* / therapy